Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players
Familial hypercholesterolemia (FH) is associated with low-grade systemic inflammation, a key driver of premature atherosclerosis. We investigated the effects of inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) function on inflammatory state, endothelial dysfunction and cardiovascular...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Elsevier
2022
|
| Subjects: | |
| Online Access: | https://doaj.org/article/18b9bb9d7ffb44ad935d98f1e616d8cd |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!